UBS Group’s Mersana Therapeutics MRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-221
Closed -$6.39K 10931
2025
Q4
$6.39K Sell
221
-8,388
-97% -$159K ﹤0.01% 8557
2025
Q3
$66.8K Sell
8,609
-22,411
-72% -$168K ﹤0.01% 7369
2025
Q2
$230K Buy
31,020
+18,228
+142% +$160K ﹤0.01% 6633
2025
Q1
$110K Buy
12,792
+6,301
+97% +$97.2K ﹤0.01% 6978
2024
Q4
$232K Sell
6,491
-12,450
-66% -$644K ﹤0.01% 6362
2024
Q3
$895K Buy
18,941
+17,542
+1,254% +$774K ﹤0.01% 4752
2024
Q2
$70.3K Sell
1,399
-10,188
-88% -$737K ﹤0.01% 6425
2024
Q1
$1.3M Buy
11,587
+5,456
+89% +$542K ﹤0.01% 4372
2023
Q4
$356K Buy
6,131
+3,853
+169% +$155K ﹤0.01% 5370
2023
Q3
$72.3K Sell
2,278
-4,667
-67% -$222K ﹤0.01% 6059
2023
Q2
$571K Sell
6,945
-471
-6% -$68.9K ﹤0.01% 4710
2023
Q1
$762K Sell
7,416
-4,128
-36% -$579K ﹤0.01% 4349
2022
Q4
$1.69M Buy
11,544
+10,492
+997% +$1.77M ﹤0.01% 3558
2022
Q3
$178K Buy
1,052
+699
+198% +$114K ﹤0.01% 5199
2022
Q2
$41K Sell
353
-252
-42% -$23.7K ﹤0.01% 6073
2022
Q1
$60K Sell
605
-6,642
-92% -$776K ﹤0.01% 6313
2021
Q4
$1.13M Buy
7,247
+3,718
+105% +$723K ﹤0.01% 4278
2021
Q3
$832K Buy
3,529
+2,592
+277% +$757K ﹤0.01% 4344
2021
Q2
$318K Sell
937
-2,546
-73% -$964K ﹤0.01% 5044
2021
Q1
$1.41M Buy
3,483
+3,229
+1,271% +$1.57M ﹤0.01% 3902
2020
Q4
$169K Buy
254
+136
+115% +$75.6K ﹤0.01% 5344
2020
Q3
$55K Buy
118
+11
+10% +$5.56K ﹤0.01% 5581
2020
Q2
$62K Sell
107
-897
-89% -$306K ﹤0.01% 5689
2020
Q1
$146K Sell
1,004
-815
-45% -$142K ﹤0.01% 4968
2019
Q4
$261K Buy
1,819
+679
+60% +$49.6K ﹤0.01% 5405
2019
Q3
$45K Buy
1,140
+840
+280% +$61.1K ﹤0.01% 6259
2019
Q2
$30K Buy
300
+240
+400% +$28.3K ﹤0.01% 6334
2019
Q1
$8K Sell
60
-232
-79% -$29.2K ﹤0.01% 6943
2018
Q4
$30K Buy
292
+159
+120% +$25.2K ﹤0.01% 6488
2018
Q3
$33K Buy
133
+59
+80% +$19.8K ﹤0.01% 6468
2018
Q2
$33K Buy
74
+9
+14% +$3.95K ﹤0.01% 6315
2018
Q1
$26K Buy
65
+14
+27% +$5.53K ﹤0.01% 6214
2017
Q4
$21K Sell
51
-13
-20% -$5.67K ﹤0.01% 6515
2017
Q3
$28K Sell
64
-3
-4% -$1.18K ﹤0.01% 6211
2017
Q2
$24K Buy
+67
New +$23.2K ﹤0.01% 6166

Other funds holding MRSN